Solid Biosciences Inc. SLDB announced that the FDA has cleared its investigational new drug (IND) application to begin ...

The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small ...

Solid Biosciences (SLDB) announced that the FDA has cleared its investigational new drug, or IND, application for SGT-212 for the treatment of Friedreich’s ataxia, a degenerative disease caused ...

The FDA has approved the investigational new drug application of 225Ac-SSO110, allowing for the start of a phase 1/2 trial in ...

Tyra Biosciences (TYRA) announced that the U.S. FDA cleared its Investigational New Drug application for TYRA-300 allowing the company to ...

SGT-212 is the company's novel, AAV-based FA gene therapy candidate designed to deliver full-length frataxin via systemic intravenous (IV) infusion as well as direct intradentate nuclei (IDN) infusion ...

Nitroxoline has not been approved by the FDA, and its use is therefore considered investigational. FLA patients will receive ...

cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 in low-grade, intermediate risk non-muscle invasive ...

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...

Solid Biosciences received clearance from the Food and Drug Administration for an investigational new drug application, the company said Tuesday.

INCHEON, South Korea, Jan. 15, 2025 /PRNewswire/ — Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, ...